/** blogpostTitle: Madhavbaug FY26: Growth returns, margins wobble as expansion spend rises */

Madhavbaug FY26: Growth returns, margins wobble as expansion spend rises

Vaidya Sane Ayurved Laboratories Limited, known through its Madhavbaug brand, closed FY26 with a rebound in reported revenue and profit, but a visible squeeze in second-half operating margins. For FY26, income from operations rose to INR 106.91 crore from INR 89.92 crore in FY25, a growth of 18.89%. EBITDA (excluding other income) increased to INR 15.42 crore from INR 14.32 crore, while PAT grew faster at INR 8.99 crore versus INR 7.15 crore.

The second half told a more mixed story. H2 FY26 revenue from operations increased 18.37% year-on-year to INR 56.96 crore, but EBITDA margin fell to 11.93% from 17.79%. Management attributed the margin pressure to higher investments in expansion, branding, technology initiatives, and a newly introduced call centre that, according to the concall, costs around INR 50 to 60 lakh per month.

The company’s operating narrative remains anchored in an “integrated” Ayurveda healthcare platform. The presentation positions Madhavbaug as a large chain of clinics and hospitals focused on lifestyle disease reversal, supported by in-house manufacturing of medicines and diet kits, and a digital layer via the MIB Pulse app and the Power MAP clinical analytics platform.

A business built on clinics, with hospitals as the next leg

Madhavbaug’s operating footprint in the presentation includes 320+ clinics across India, 450+ Ayurveda physicians, and over 10 lakh patients treated. The hospital network is shown as four operational facilities with 134+ beds: Khopoli (45), Kondhali near Nagpur (30), Vizag (24), and Vadodara (35).

A key lens in the company’s disclosures is “enterprise collection”, which includes collections from franchise clinics, not just the listed entity’s reported revenue. For FY26, enterprise collection is presented at INR 196.91 crore, split between clinics at INR 166.55 crore and hospitals at INR 30.36 crore.

Within clinics, FY26 clinic enterprise collection is shown as services at INR 103.17 crore and products at INR 63.38 crore. The presentation also frames the business as clinic-led with hospitals as a smaller but growing contributor, while management on the call described an intent for a more balanced mix between clinics and hospitals over the medium term.

Financial summary (reported)

The strategic pivot: from preventive care to higher-ticket “disease reversal”

Management repeatedly emphasized a deliberate shift in revenue mix. Historically, the company described itself as more exposed to preventive healthcare programs with lower ticket sizes. The concall described a pivot toward specialized disease reversal programs targeting cardiac disorders, diabetes, hypertension, obesity, and related lifestyle disorders.

The stated economics highlight why this pivot matters. Management said preventive care programs typically generate about INR 10,000 to INR 13,000 annually per new patient, while disease reversal programs are in the INR 50,000 to INR 60,000 range per patient annually. For hospitals, the presentation cites INR 4 to 5 lakh average revenue per bed per month. Management also mentioned a hospital blended ARPU of about INR 70,000.

The operating engine behind this strategy is scale and standardisation. The presentation describes standardized Panchakarma procedures, diet management via in-house kits, and in-house manufactured herbal medicines. The 12-month patient protocol is split between a 3-month “aggressive” phase and a 9-month “conservative” phase, with progress tracked digitally via the MIB Pulse app.

Hospitals: utilization and capacity expansion are the near-term execution test

Hospital performance in the presentation shows a ramp-up at the flagship Khopoli hospital, with half-year revenues increasing from INR 8.30 crore in H1 FY25 to INR 11.51 crore in H2 FY26. Kondhali shows steady growth, while Vizag and Vadodara remain smaller contributors given their newer vintage.

In the concall, management provided occupancy estimates: Khopoli at 90% to 100%, Nagpur at 70% to 80%, Vizag at 50% to 60%, and Vadodara at 30% to 40%. They also reiterated the plan to scale bed capacity from 134+ to 250-300 beds in 12-15 months. More granularly, management said the Khopoli expansion is under construction and guided to having 150 constructed beds by March 2027, while Nagpur expansion is pending government permissions. Vadodara was described as a rental model, with additional bed capacity possible after higher occupancy.

New moves: Parasnath acquisition, Malaysia JV, and Urja Neuro Care

FY26 also carried multiple expansion initiatives beyond core cardiac and diabetes care.

The investor presentation announced a proposed acquisition of Parasnath Healthcare (OPC) Private Limited for INR 6.0 crore for 100% stake, subject to approvals. The rationale provided is expansion into specialized pain management and clinic operations, consolidation of franchise operations, and synergy creation.

On the concall, management added that Parasnath is a chain of about 70 franchise clinics focused on joint pain treatment through Ayurveda, with net turnover of about INR 14 crore and EBITDA of about INR 1.1 crore. Management also stated cross-referral opportunities between Madhavbaug clinics and hospitals and the Parasnath network.

International expansion was highlighted via a Malaysia partnership with Maxura Healthcare structured as a 70:30 profit-sharing JV. The presentation describes Madhavbaug’s role as providing clinical IP, standardized protocols and physician training, while the partner handles local operations and regulatory approvals. Management described this as an asset-light template for further global growth.

The company also introduced Urja Neuro Care as a new vertical focused on neurological disorders. The presentation states an investment of INR 1.8 crore and positions it as a pilot initiative in FY26.

The margin question: growth is visible, but spending discipline will be watched

The most important debate in H2 FY26 was the decline in EBITDA margin. The financial table in the presentation shows “other expenses” rising sharply in H2 FY26 to INR 30.95 crore from INR 21.05 crore in H2 FY25, contributing to EBITDA decline despite revenue growth.

Management linked the increase to investments toward expansion, branding, technology and strengthening operations. They also directly attributed the H2 margin decline to the introduction of a call centre and stated its monthly cost at around INR 50 to 60 lakh. Investors also pushed for greater disclosure granularity on “other expenses”.

On guidance, management stated a revenue target of INR 170 to 180 crore for FY27 and medium-term revenue potential of INR 250 to 300 crore by FY28, while targeting EBITDA margins above 20%. Management also spoke about a medium-term target of 2 lakh new patients annually till FY28, supported by stronger brand awareness, digital engagement and increased insurance coverage.

Takeaways

Madhavbaug’s FY26 shows a return to reported revenue growth and improving PAT, but the margin profile remains sensitive to discretionary spending, especially marketing and engagement infrastructure. The strategic path is clear in management commentary: move up the value chain through disease reversal programs and scale hospital capacity, while using the franchise model to expand clinic reach with lower capex.

The next milestones will likely be measured in hospital bed additions and utilization, insurance empanelment progress outside the flagship facility, and whether higher marketing and engagement spends translate into stronger patient additions and conversion into higher-ticket programs. Management’s FY27 revenue target of INR 170 to 180 crore sets a demanding execution bar, making FY27 a key year for validation of the expansion-led strategy.